Navigation Links
AutoImmune Inc. Reports 2008 Fourth Quarter and Year End Financial Results
Date:3/16/2009

multiple sclerosis.

AutoImmune also announced today that its Annual Meeting of Shareholders will be held on Friday, May 22, 2009, at 11:00 a.m. EDT, at the offices of Nutter, McClennen & Fish, 155 Seaport Blvd. in Boston, Massachusetts. AutoImmune is a biopharmaceutical company involved in the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.

Statements in this release that are not strictly historical are forward-looking statements including statements about clinical trials and studies and future sales, royalties and revenue. You can identify these forward-looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to the uncertainties of clinical trial results, the Company's dependence on third parties for licensing revenue, and the risks of technological change and competition. These factors are more fully discussed, as are other factors, in the Company's most recent Annual Report on Form 10-KSB filed with the Securities and Exchange Commission in the section entitled "Risk Factors."

- Financial Chart Follows -


                                 AUTOIMMUNE INC.
                             STATEMENT OF OPERATIONS
                                   (Unaudited)

                                 Three months ended           Year ended
                                     December 31,            December 31,
                                   2007        2008        2007        2008
                                   ----        ----   
'/>"/>
SOURCE AutoImmune Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Advances in Detection Technology Drive the European Autoimmune Disease Diagnostics Market
2. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
3. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
4. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
5. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
6. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
7. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
8. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
9. Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results
10. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
11. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... and HILDEN, Germany , May ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... Clinical Insight ® (QCI™) bioinformatics content and ... and report on genomic variants identified in next-generation ... the bioinformatics platform are in oncology, for somatic ...
(Date:5/26/2015)... 26, 2015  Alere Inc. (NYSE: ALR ) (the ... to timely file its Quarterly Report on Form 10-Q for ... it has received a notice from the New York Stock ... with the NYSE,s continued listing requirements under the timely filing ... Manual. The reason for the delay relates ...
(Date:5/26/2015)... NJ (PRWEB) May 26, 2015 OHAUS ... balances and scales, is set to release a new ... of quality-driven laboratory instruments. For over a century, the ... in weighing technology throughout the world. Now in ... has gone Beyond Weighing to include water quality measurement. ...
(Date:5/26/2015)... ANGELES , May 26, 2015 Pharmaco-Kinesis ... Board (NOCAB) recently convened at Shutters on the Beach ... review the development status of the Company,s innovative Metronomic ... designed to locally deliver chemotherapy over time to a ... dose delivery capacity and biofeedback system in real-time.  ...
Breaking Biology Technology:QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 2QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 4QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 5OHAUS Corporation to Release New Water Analysis Meters in 2015 2OHAUS Corporation to Release New Water Analysis Meters in 2015 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5
... Tengion, Inc. (Nasdaq: TNGN ), a leader ... definitive agreements with certain investors in connection with a PIPE ... of 1933, as amended.  Medtronic (NYSE: MDT ), ... and, as part of its investment, secured a right of ...
... Iverson Genetic Diagnostics, Inc. announced today that the WARFARIN ... eduction f or A dults R eceiving ... Overlake Hospital Medical Center in Bellevue and other major hospital ... determine a personalized warfarin dose for individual patients to reduce ...
... 28, 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation (NYSE: ... of cord blood collection, laboratory testing, hematopoietic stem cell processing, ... for the third quarter and first nine months of fiscal ... Quarter of Fiscal 2011 ...
Cached Biology Technology:Tengion Announces Pricing of $31.4 Million Private Placement 2Tengion Announces Pricing of $31.4 Million Private Placement 3WARFARIN Study Launched at Overlake Hospital Medical Center to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 2WARFARIN Study Launched at Overlake Hospital Medical Center to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 3WARFARIN Study Launched at Overlake Hospital Medical Center to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 4China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 2China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 3China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 4China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 5China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 6China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 7China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 8China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 9China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 10China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 11
(Date:5/19/2015)... , May 19, 2015 ... announced the addition of the  "Genetic Testing ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, ... in-depth analysis of the current and future ... gene-based tests, their working principles and types ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated ... human interface solutions, today announced the appointment of ... and Chief Financial Officer, reporting to Rick ... Synaptics, current Chief Financial Officer, Kathleen Bayless ... Mr. Ali brings extensive financial ...
(Date:5/8/2015)... , May 8, 2015 Synaptics Inc. (NASDAQ: ... today announced that members of the executive management team will ... 43rd Annual Technology, Media and Telecom Conference Date: May ... in Boston, MA Cowen ... 2015 Time: 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Synaptics to Present at Upcoming Investor Conferences 2
... December 17th, 2013 - Eurofins Medigenomix, a part of ... Orion Diagnostica Oy, an in vitro diagnostics company specialising ... systems, announced that they have signed a co-exclusive technology ... for the SIBA isothermal nucleic acid detection technology in ...
... birth to live young, rather than laid eggs, and over ... reproductive mode, according to research published in print in ... unusual and controversial finding, and a major overturn of an ... Assistant Professor of Biology in the Columbian College of Arts ...
... controlling the temperature of silica rods as they grow, ... Laboratory could be setting the stage for advances in ... and more. The goal of fabricating fixed-size one-dimensional ... diameter during growth has long eluded scientists. Now, Panos ...
Cached Biology News:Ancestor of snakes, lizards likely gave birth to live young 2ORNL devises recipe to fine-tune diameter of silica rods 2
... This thin foil heat sealing material ... pressure from a screw down heated ... is a useful method for sample ... over the existing seal. Ideal for ...
... This product has been developed to significantly ... labeled proteins. Stability is increased at ... 2-8 centigrade. This product is subjected ... mercury or azide. This formulation insures ...
... Western Blot Strong Antibody Stripping Solution is ... blots that have been developed with chemiluminescence ... is not recommended for stripping colorimetric substrates ... not possible to effectively remove substrates that ...
...
Biology Products: